INPP1

Summary

INPP1 (inositol polyphosphate-1-phosphatase, HGNC:6071) is a protein-coding gene on chromosome 2q32.2, encoding Inositol polyphosphate 1-phosphatase (P49441). Mg(2+)-dependent phosphatase that catalyzes the hydrolysis of the 1-position phosphate from inositol 1,4-bisphosphate and inositol 1,3,4-trisphosphate and participates in inositol phosphate metabolism.

This gene encodes the enzyme inositol polyphosphate-1-phosphatase, one of the enzymes involved in phosphatidylinositol signaling pathways. This enzyme removes the phosphate group at position 1 of the inositol ring from the polyphosphates inositol 1,4-bisphosphate and inositol 1,3,4-trisphophosphate.

Source: NCBI Gene 3628 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 70 total
• MANE Select transcript: NM_001128928

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6071
Approved symbol	INPP1
Name	inositol polyphosphate-1-phosphatase
Location	2q32.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000151689
Ensembl biotype	protein_coding
OMIM	147263
Entrez	3628

Gene structure

Transcript identifiers

Ensembl transcripts: 41 — 37 protein_coding, 2 protein_coding_CDS_not_defined, 2 retained_intron

ENST00000322522, ENST00000392329, ENST00000409027, ENST00000413239, ENST00000417336, ENST00000422454, ENST00000423767, ENST00000430311, ENST00000431594, ENST00000444194, ENST00000451089, ENST00000458193, ENST00000458647, ENST00000470892, ENST00000487628, ENST00000889764, ENST00000889765, ENST00000889766, ENST00000889767, ENST00000889768, ENST00000889769, ENST00000889770, ENST00000889771, ENST00000889772, ENST00000889773, ENST00000889774, ENST00000889775, ENST00000889776, ENST00000889777, ENST00000889778, ENST00000926888, ENST00000926889, ENST00000956157, ENST00000956158, ENST00000956159, ENST00000956160, ENST00000956161, ENST00000956162, ENST00000956163, ENST00000956164, ENST00000956165

RefSeq mRNA: 2 — MANE Select: NM_001128928 NM_001128928, NM_002194

CCDS: CCDS2305

Canonical transcript exons

ENST00000392329 — 7 exons

Exon	Start	End
ENSE00001360415	190343589	190343961
ENSE00001511479	190348888	190349031
ENSE00003482054	190360039	190360306
ENSE00003785011	190362627	190362687
ENSE00003889567	190369103	190369277
ENSE00003891988	190366695	190366895
ENSE00003892394	190370844	190371665

Expression profiles

Bgee: expression breadth ubiquitous, 293 present calls, max score 99.16.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 18.8310 / max 325.6449, expressed in 1725 samples.

FANTOM5 promoters (13 alternative TSS)

Promoter ID	TPM avg	Samples expressed
24276	12.5075	1662
24278	2.6103	1290
24277	0.7414	434
24287	0.7373	206
24288	0.6722	135
24280	0.4307	177
24279	0.3234	140
24285	0.2848	141
24281	0.1989	83
24289	0.1150	66

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	99.16	gold quality
male germ cell	CL:0000015	98.57	gold quality
esophagus squamous epithelium	UBERON:0006920	97.63	gold quality
corpus callosum	UBERON:0002336	97.34	gold quality
epithelium of esophagus	UBERON:0001976	97.33	gold quality
middle frontal gyrus	UBERON:0002702	96.86	gold quality
squamous epithelium	UBERON:0006914	96.65	gold quality
esophagus mucosa	UBERON:0002469	96.48	gold quality
pharyngeal mucosa	UBERON:0000355	95.89	gold quality
cervix epithelium	UBERON:0004801	95.78	gold quality
left testis	UBERON:0004533	95.56	gold quality
inferior vagus X ganglion	UBERON:0005363	95.56	gold quality
epithelium of nasopharynx	UBERON:0001951	95.51	gold quality
cervix squamous epithelium	UBERON:0006922	95.37	gold quality
right testis	UBERON:0004534	95.33	gold quality
duodenum	UBERON:0002114	95.27	gold quality
right lung	UBERON:0002167	95.11	gold quality
epithelial cell of pancreas	CL:0000083	95.10	gold quality
pons	UBERON:0000988	94.95	gold quality
jejunal mucosa	UBERON:0000399	94.84	gold quality
tongue squamous epithelium	UBERON:0006919	94.75	gold quality
upper leg skin	UBERON:0004262	94.72	gold quality
mucosa of urinary bladder	UBERON:0001259	94.63	gold quality
testis	UBERON:0000473	94.54	gold quality
ileal mucosa	UBERON:0000331	94.47	gold quality
gingival epithelium	UBERON:0001949	94.45	gold quality
esophagus	UBERON:0001043	94.38	gold quality
gingiva	UBERON:0001828	94.23	gold quality
vagina	UBERON:0000996	94.21	gold quality
oral cavity	UBERON:0000167	94.07	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

24 targeting INPP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-3681-3P	99.88	70.46	2254
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-4756-3P	99.62	66.30	1319
HSA-MIR-203A-3P	99.49	70.56	2806
HSA-MIR-16-2-3P	99.29	70.60	1954
HSA-MIR-195-3P	99.29	70.61	1954
HSA-MIR-583	98.71	67.44	1791
HSA-MIR-302F	98.44	69.02	1776
HSA-MIR-653-3P	98.31	67.71	1542
HSA-MIR-634	97.74	67.11	818

Literature-anchored findings (GeneRIF, showing 4)

• association study performed between the 5’ regulatory region of the serotonin transporter gene (5-HTTLPR), the inositol polyphosphate 1-phosphatase gene (INPP1) and bipolar disorder using our sample of proband/parent trios (PMID:11901356)
• results suggest that genetic variability at rs669838-IMPA2,rs4853694-INPP1, rs1732170-GSK3b and rs11921360-GSK3b genes is associated with a higher risk of attempting suicide in bipolar patients. (PMID:23453640)
• High INPP1 expression is associated with cancer aggressiveness. (PMID:24738946)
• We found the suicide-associated gene coexpression network. The reconstructed network consisted of 104 genes. Topological analysis showed that in total, CCK, INPP1, DDC, and NPY genes are the most fundamental hubs in the network (PMID:29381655)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	si:ch211-160o17.2	ENSDARG00000002897
mus_musculus	Inpp1	ENSMUSG00000026102
rattus_norvegicus	Inpp1	ENSRNOG00000012375
drosophila_melanogaster	Ipp	FBGN0016672

Paralogs (4): BPNT2 (ENSG00000104331), IMPA1 (ENSG00000133731), IMPA2 (ENSG00000141401), BPNT1 (ENSG00000162813)

Protein

Protein identifiers

Inositol polyphosphate 1-phosphatase — P49441 (reviewed: P49441)

All UniProt accessions (11): P49441, A0A1D5RMQ4, B8ZZF6, C9J128, C9J173, C9J2N5, C9J2Z6, E7ENF2, E7ET59, E7EUX4, Q6IBG4

UniProt curated annotations — full annotation on UniProt →

Function. Mg(2+)-dependent phosphatase that catalyzes the hydrolysis of the 1-position phosphate from inositol 1,4-bisphosphate and inositol 1,3,4-trisphosphate and participates in inositol phosphate metabolism.

Subunit / interactions. Monomer.

Tissue specificity. Ubiquitously expressed, with highest levels in pancreas and kidney.

Activity regulation. Inhibited by Li(+).

Pathway. Signal transduction; phosphatidylinositol signaling pathway.

Similarity. Belongs to the inositol monophosphatase superfamily.

RefSeq proteins (2): NP_001122400, NP_002185 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000760	Inositol_monophosphatase-like	Family
IPR020550	Inositol_monophosphatase_CS	Conserved_site
IPR020583	Inositol_monoP_metal-BS	Binding_site
IPR044897	INPP1_dom_1	Homologous_superfamily
IPR050725	CysQ/Inositol_MonoPase	Family

Pfam: PF00459

Enzyme classification (BRENDA):

• EC 3.1.3.57 — inositol-1,4-bisphosphate 1-phosphatase (BRENDA: 7 organisms, 16 substrates, 13 inhibitors, 9 Km, 0 kcat entries)

Substrate kinetics (BRENDA)

2 substrates with measured Km, best-characterized 2. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
INOSITOL 1,3,4-TRISPHOSPHATE	0.011–0.031	3
INOSITOL 1,4-BISPHOSPHATE	0.0009–0.2	3

Catalyzed reactions (Rhea), 2 shown:

• 1D-myo-inositol 1,4-bisphosphate + H2O = 1D-myo-inositol 4-phosphate + phosphate (RHEA:15553)
• 1D-myo-inositol 1,3,4-trisphosphate + H2O = 1D-myo-inositol 3,4-bisphosphate + phosphate (RHEA:70319)

UniProt features (20 total): binding site 16, sequence variant 2, chain 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P49441-F1	87.87	0.69

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (16): 54; 267; 269; 289; 290; 293; 311; 316; 79; 80; 153; 153 …

Post-translational modifications (1): 317

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-1855183	Synthesis of IP2, IP, and Ins in the cytosol
R-HSA-1430728	Metabolism
R-HSA-1483249	Inositol phosphate metabolism

MSigDB gene sets: 232 (showing top): GSE18804_BRAIN_VS_COLON_TUMORAL_MACROPHAGE_DN, GOBP_PHOSPHOLIPID_METABOLIC_PROCESS, GOBP_PHOSPHATIDYLINOSITOL_METABOLIC_PROCESS, KAAB_HEART_ATRIUM_VS_VENTRICLE_UP, KYNG_DNA_DAMAGE_DN, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, NAGASHIMA_NRG1_SIGNALING_UP, GOBP_ORGANOPHOSPHATE_BIOSYNTHETIC_PROCESS, BEIER_GLIOMA_STEM_CELL_DN, GOBP_PHOSPHOLIPID_BIOSYNTHETIC_PROCESS, BILD_HRAS_ONCOGENIC_SIGNATURE, GOBP_GLYCEROLIPID_METABOLIC_PROCESS, MODULE_66, FOSTER_TOLERANT_MACROPHAGE_UP, MILI_PSEUDOPODIA_HAPTOTAXIS_UP

GO Biological Process (3): phosphate-containing compound metabolic process (GO:0006796), signal transduction (GO:0007165), phosphatidylinositol phosphate biosynthetic process (GO:0046854)

GO Molecular Function (5): inositol-1,4-bisphosphate 1-phosphatase activity (GO:0004441), metal ion binding (GO:0046872), inositol-1,3,4-trisphosphate 1-phosphatase activity (GO:0052829), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (1): cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Inositol phosphate metabolism	1
Metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
metabolic process	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
glycerophospholipid biosynthetic process	1
inositol bisphosphate phosphatase activity	1
cation binding	1
inositol trisphosphate phosphatase activity	1
binding	1
catalytic activity	1
cytoplasm	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1137 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
INPP1	ADRA1B	P35368	766
INPP1	IMPA2	O14732	668
INPP1	SLC25A12	O75746	639
INPP1	ITGA4	P13612	617
INPP1	STK39	Q9UEW8	609
INPP1	IMPA1	P29218	583
INPP1	ISYNA1	Q9NPH2	575
INPP1	CTLA4	P16410	549
INPP1	INPP5J	Q15735	538
INPP1	IPPK	Q9H8X2	528
INPP1	PPA1	Q15181	507
INPP1	CDIPT	O14735	466
INPP1	MFSD6	Q6ZSS7	443
INPP1	MINPP1	Q9UNW1	436
INPP1	IP6K3	Q96PC2	433

IntAct

11 interactions, top by confidence:

A	B	Type	Score
INPP1	MEOX2	psi-mi:“MI:0915”(physical association)	0.560
	TK2	psi-mi:“MI:0915”(physical association)	0.400
DYNLL1	INPP1	psi-mi:“MI:0915”(physical association)	0.370
PRNP	CARNS1	psi-mi:“MI:0914”(association)	0.350
S100A6	VWA8	psi-mi:“MI:0914”(association)	0.350
CCR1	UBA6	psi-mi:“MI:0914”(association)	0.350
CDH5	ESYT2	psi-mi:“MI:2364”(proximity)	0.270
INPP1	LIG1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (35): MEOX2 (Two-hybrid), NR1D1 (Two-hybrid), LDOC1 (Two-hybrid), INPP1 (Positive Genetic), PLOD1 (Positive Genetic), INPP1 (Positive Genetic), INPP1 (Positive Genetic), INPP1 (Positive Genetic), INPP1 (Positive Genetic), INPP1 (Positive Genetic), NOS2 (Positive Genetic), INPP1 (Positive Genetic), INPP1 (Affinity Capture-MS), INPP1 (Affinity Capture-MS), INPP1 (Affinity Capture-RNA)

ESM2 similar proteins: A2XEX2, D4AD37, F1RT67, F6Y5S8, O00757, O20252, O49623, O64422, P00636, P00637, P09195, P09199, P09467, P14766, P19112, P21327, P22418, P25851, P32179, P46275, P46276, P46283, P49441, P49442, P70695, Q05079, Q07204, Q14703, Q28CL4, Q29JH0, Q2KJ53, Q2KJJ9, Q2YDR3, Q38945, Q3SZB7, Q42796, Q43139, Q6NTW5, Q80V26, Q84VY5

Diamond homologs: P21327, P49441, P49442

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

70 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	50
Likely benign	5
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1592 predictions. Top by Δscore:

Variant	Effect	Δscore
2:190360026:T:A	acceptor_gain	1.0000
2:190360029:A:AG	acceptor_gain	1.0000
2:190360037:A:AG	acceptor_gain	1.0000
2:190360038:G:GG	acceptor_gain	1.0000
2:190360277:G:GT	donor_gain	1.0000
2:190360303:CAAGG:C	donor_loss	1.0000
2:190369099:TCA:T	acceptor_loss	1.0000
2:190369100:CAGAT:C	acceptor_loss	1.0000
2:190369101:A:AG	acceptor_gain	1.0000
2:190369101:A:C	acceptor_loss	1.0000
2:190369102:G:GC	acceptor_gain	1.0000
2:190369102:GATTC:G	acceptor_gain	1.0000
2:190369274:TCAG:T	donor_loss	1.0000
2:190369275:CAG:C	donor_loss	1.0000
2:190369276:AG:A	donor_loss	1.0000
2:190369277:GGTAA:G	donor_loss	1.0000
2:190348864:T:G	acceptor_gain	0.9900
2:190348871:AAAAT:A	acceptor_gain	0.9900
2:190348872:A:G	acceptor_gain	0.9900
2:190360020:C:G	acceptor_gain	0.9900
2:190360030:T:G	acceptor_gain	0.9900
2:190360034:TCCA:T	acceptor_loss	0.9900
2:190360035:CCA:C	acceptor_loss	0.9900
2:190360037:AGCT:A	acceptor_gain	0.9900
2:190360038:G:GA	acceptor_loss	0.9900
2:190360038:GC:G	acceptor_gain	0.9900
2:190360038:GCT:G	acceptor_gain	0.9900
2:190360038:GCTG:G	acceptor_gain	0.9900
2:190360273:AC:A	donor_gain	0.9900
2:190362605:C:CA	acceptor_gain	0.9900

AlphaMissense

2607 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:190371145:T:A	W315R	0.999
2:190371145:T:C	W315R	0.999
2:190371147:G:C	W315C	0.998
2:190371147:G:T	W315C	0.998
2:190371149:A:C	D316A	0.998
2:190366880:T:A	W151R	0.997
2:190366880:T:C	W151R	0.997
2:190369249:T:C	F205L	0.997
2:190369251:T:A	F205L	0.997
2:190369251:T:G	F205L	0.997
2:190371081:G:C	K293N	0.997
2:190371081:G:T	K293N	0.997
2:190371149:A:T	D316V	0.997
2:190366887:A:G	D153G	0.996
2:190371150:C:A	D316E	0.996
2:190371150:C:G	D316E	0.996
2:190360158:C:A	A19D	0.995
2:190369105:T:C	S157P	0.995
2:190371139:T:C	F313L	0.995
2:190371141:C:A	F313L	0.995
2:190371141:C:G	F313L	0.995
2:190371149:A:G	D316G	0.995
2:190362658:A:T	E79V	0.994
2:190370995:A:C	S265R	0.994
2:190370997:T:A	S265R	0.994
2:190370997:T:G	S265R	0.994
2:190371156:T:G	C318W	0.994
2:190360145:G:C	A15P	0.993
2:190366893:T:A	I155K	0.993
2:190369104:T:A	D156E	0.993

dbSNP variants (sampled 300 via entrez): RS1000022965 (2:190348033 G>A), RS1000104334 (2:190370023 A>G), RS1000193353 (2:190355322 C>T), RS1000245630 (2:190355635 T>C), RS1000282108 (2:190368977 C>A,T), RS1000321623 (2:190342098 T>C), RS1000586630 (2:190368580 G>T), RS1000588864 (2:190341726 T>G), RS1000795982 (2:190343620 A>G), RS1000828835 (2:190343391 G>A,T), RS1000862211 (2:190362166 A>G), RS1000973284 (2:190353559 T>C,G), RS1001123727 (2:190346796 G>C), RS1001163948 (2:190349902 T>C), RS1001238556 (2:190353169 G>A)

Disease associations

OMIM: gene MIM:147263 | disease phenotypes:

GenCC curated gene-disease

Mondo (2): retinal disorder (MONDO:0005283), cleft palate (MONDO:0016064)

Orphanet (1): Cleft palate (Orphanet:2014)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST003518_14	Daytime sleep phenotypes	3.000000e-06
GCST003518_96	Daytime sleep phenotypes	5.000000e-06
GCST006866_1	Lung cancer (SNP x SNP interaction)	1.000000e-13
GCST010248_2	Machado-Joseph disease (age at onset)	6.000000e-06
GCST90010715_5	Arthritis (juvenile idiopathic)	1.000000e-09

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0007828	daytime rest measurement
EFO:0004847	age at onset

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D002972	Cleft Palate	C05.500.460.185; C05.660.207.540.460.185; C07.320.440.185; C07.465.525.185; C07.650.500.460.185; C07.650.525.185; C16.131.621.207.540.460.185; C16.131.850.500.460.185; C16.131.850.525.185
D012164	Retinal Diseases	C11.768

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — Inositol polyphosphate phosphatases

CTD chemical–gene interactions

60 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases methylation, increases expression, increases mutagenesis	7
Aflatoxin B1	increases expression, affects expression, decreases methylation	4
Air Pollutants	affects cotreatment, increases abundance, increases expression, decreases expression	3
Cisplatin	affects expression, increases expression	3
Phenylmercuric Acetate	increases expression, affects cotreatment	2
Tretinoin	increases expression	2
Valproic Acid	increases expression	2
Cyclosporine	increases expression	2
Particulate Matter	decreases expression, increases abundance, increases expression	2
aristolochic acid I	increases expression	1
alpha-pinene	affects cotreatment, increases expression, increases abundance	1
bisphenol A	affects expression	1
trichostatin A	increases expression	1
beta-lapachone	increases expression	1
arsenite	affects binding, increases reaction	1
sulforaphane	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
periodate-oxidized adenosine	affects expression	1
methacrylaldehyde	increases expression, increases abundance, affects cotreatment	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
S 1 (combination)	increases response to substance	1
CGP 52608	affects binding, increases reaction	1
K 7174	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
nutlin 3	affects cotreatment, increases expression, increases secretion	1
belinostat	decreases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
PCI 5002	affects cotreatment, increases expression	1

Clinical trials (associated diseases)

107 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01955135	PHASE4	COMPLETED	Anesthesia for Retinopathy of Prematurity
NCT02422056	PHASE4	COMPLETED	Acid Tranexamic Effectiveness in Reducing the Intraoperative Bleeding in Palatoplasty
NCT02915042	PHASE4	WITHDRAWN	Dexmedetomidine vs Placebo for Pediatric Cleft Palate Repair
NCT02953145	PHASE4	WITHDRAWN	The Use of Fibrin Sealant to Reduce Post Operative Pain in Cleft Palate Surgery
NCT03632044	PHASE4	ACTIVE_NOT_RECRUITING	Evaluation of Trigeminal Nerve Blockade
NCT06962306	PHASE4	RECRUITING	Optimizing Perioperative Analgesia to Lower Pain Following Cleft Palate Surgery
NCT00098319	PHASE3	COMPLETED	Oral Cleft Prevention Trial in Brazil
NCT00397917	PHASE3	COMPLETED	Oral Cleft Prevention Program
NCT04928352	PHASE3	RECRUITING	Nebulized Bupivacaine Analgesia for Cleft Palate Repair
NCT04928391	PHASE3	COMPLETED	A Single Bolus of Dexmedetomidine Versus Normal Saline in Postoperative Agitation
NCT01373476	PHASE2	COMPLETED	Multicentre, Randomized, Controlled Trial of Qideng Mingmu Capsule in The Treatment of Diabetic Retinopathy
NCT01793090	PHASE2	COMPLETED	EPI-743 in Cobalamin C Defect: Effects on Visual and Neurological Impairment
NCT00004639	PHASE2	COMPLETED	Cleft Palate Surgery and Speech Development
NCT00760006	PHASE2	COMPLETED	Preventing Complications in Cleft Palate Repair With Antibiotics
NCT01760330	PHASE2	WITHDRAWN	IV Acetaminophen in Children Undergoing Palatoplasty
NCT02350803	PHASE2	COMPLETED	Does Use of Rigid Fixation After Removing Distraction Osteogenesis Device Reduce the Relapse?
NCT03412474	PHASE2	COMPLETED	Suprazygomatic Block in Cleft Palate Surgery in Children
NCT04311112	PHASE2/PHASE3	WITHDRAWN	Safety and Efficacy of Zuretinol Acetate in Subjects With Inherited Retinal Disease
NCT04008121	EARLY_PHASE1	RECRUITING	Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
NCT00259701	Not specified	COMPLETED	Microvascular Reactivity.
NCT00331370	Not specified	UNKNOWN	Hypertension Related Damage to the Microcirculation in South Asian: Emergence, Predictive Power and Reversibility
NCT00618644	Not specified	WITHDRAWN	Ranibizumab for Neovascularization in Sickle Cell Retinopathy
NCT00735657	Not specified	COMPLETED	Anesthesia for Pars Plana Vitrectomy (PPV) With Insulin Needle
NCT00828425	Not specified	COMPLETED	Management of Diabetes Mellitus Patients With Retinopathy
NCT00969956	Not specified	TERMINATED	Time To Complications Occurs in Diabetes
NCT01412905	Not specified	COMPLETED	Telemedicine Retinal Screening Utilizing a Mobile Medical Unit
NCT01546766	Not specified	COMPLETED	Rapid, Non-invasive, Regional Functional Imaging of the Retina. (Diabetic Retinopathy Diagnosis Device)
NCT01552993	Not specified	TERMINATED	Registration and Treatment of Pain During Eye Examination of Prematurity
NCT01815567	Not specified	COMPLETED	DETECT and Retinal Outcomes in Hypertension
NCT02321904	Not specified	COMPLETED	Corneal Confocal Microscopy to Detect Diabetic Neuropathy in Children
NCT02466607	Not specified	COMPLETED	Study of Stimulus Parameters in Flicker Electroretinogram (ERG)
NCT02558478	Not specified	UNKNOWN	Identification of New Genes Implicated in Rare Neurosensory Diseases by Whole Exome Sequencing
NCT02702973	Not specified	UNKNOWN	Characteristic Analysis of Retinopathy Associated With High Doses of Interferon α-2b Therapy
NCT03011541	Not specified	RECRUITING	Stem Cell Ophthalmology Treatment Study II
NCT03542734	Not specified	RECRUITING	Cognitive Impairment, Retinopathy, and Cerebrovascular Lesions in the Elderly
NCT03901898	Not specified	COMPLETED	Feasibility of an Intervention to Increase Diabetic Retinopathy Screening Attendance
NCT04819893	Not specified	RECRUITING	Study of the Involvement of Fatty Acids in Retinopathy of Prematurity: Relationship Between Retinopathy of Prematurity and the Rate of Expression of Transplacental Fatty Acid Receptors.
NCT05921981	Not specified	COMPLETED	Multisensory Stimulation Versus White Noise
NCT06239064	Not specified	ACTIVE_NOT_RECRUITING	Early Genetic Identification of Obesity
NCT06355219	Not specified	COMPLETED	Macrovascular and Microvascular Morbidity and Mortality After Metabolic Surgery Versus Medicines